IS6162A - Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður - Google Patents

Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður

Info

Publication number
IS6162A
IS6162A IS6162A IS6162A IS6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A IS 6162 A IS6162 A IS 6162A
Authority
IS
Iceland
Prior art keywords
amyloid
clustering
inhibiting
proteins
image
Prior art date
Application number
IS6162A
Other languages
English (en)
Inventor
Elizabeth Auhelli-Szafran Corinne
Lai Yingjie
Theresa Sakkab Annette
Craswell Walker Lary
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of IS6162A publication Critical patent/IS6162A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS6162A 1999-06-10 2001-11-15 Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður IS6162A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10
PCT/US2000/015073 WO2000076969A1 (en) 1999-06-10 2000-05-31 Method of inhibiting amyloid protein aggregation and imaging amyloid deposits using isoindoline derivatives

Publications (1)

Publication Number Publication Date
IS6162A true IS6162A (is) 2001-11-15

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6162A IS6162A (is) 1999-06-10 2001-11-15 Aðferð til að tálma þyrpingu amýloið-protína og til að fá mynd af útfellingum amylóiðs með því að nota ísóindólín-afleiður

Country Status (38)

Country Link
EP (1) EP1192131B1 (is)
JP (1) JP2003502313A (is)
KR (1) KR20020012266A (is)
CN (1) CN1156445C (is)
AP (1) AP1398A (is)
AT (1) ATE272623T1 (is)
AU (1) AU777747B2 (is)
BG (1) BG106291A (is)
BR (1) BR0011446A (is)
CA (1) CA2373394A1 (is)
CR (1) CR6530A (is)
CZ (1) CZ20014366A3 (is)
DE (1) DE60012742T2 (is)
DK (1) DK1192131T3 (is)
DZ (1) DZ3262A1 (is)
EA (1) EA004405B1 (is)
EE (1) EE200100666A (is)
ES (1) ES2223531T3 (is)
GE (1) GEP20043407B (is)
HK (1) HK1046283B (is)
HR (1) HRP20020027A2 (is)
HU (1) HUP0201586A2 (is)
IL (1) IL146455A0 (is)
IS (1) IS6162A (is)
MA (1) MA26807A1 (is)
MX (1) MXPA01011112A (is)
NO (1) NO20015992L (is)
NZ (1) NZ515619A (is)
OA (1) OA11958A (is)
PL (1) PL352294A1 (is)
PT (1) PT1192131E (is)
SI (1) SI1192131T1 (is)
SK (1) SK17622001A3 (is)
TR (1) TR200200257T2 (is)
UA (1) UA64842C2 (is)
WO (1) WO2000076969A1 (is)
YU (1) YU86801A (is)
ZA (1) ZA200109164B (is)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
IL146971A0 (en) * 1999-06-10 2002-08-14 Warner Lambert Co Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) * 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
SG173409A1 (en) * 2006-11-24 2011-08-29 Ac Immune Sa N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimers
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
ES2714453T3 (es) * 2008-06-09 2019-05-28 Univ Muenchen Ludwig Maximilians Fármacos para inhibir la agregación de proteínas implicadas en enfermedades relacionadas con enfermedades neurodegenerativas y/o agregación de proteínas
CN102325765B (zh) 2009-02-06 2014-12-24 杨森制药公司 作为γ-分泌酶调节剂的取代的双环杂环化合物
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EA019702B1 (ru) * 2009-05-07 2014-05-30 Янссен Фармасьютикалз, Инк. Замещенные производные индазола и азаиндазола в качестве модуляторов гамма-секретазы
WO2011006903A1 (en) 2009-07-15 2011-01-20 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Substituted triazole and imidazole derivatives as gamma secretase modulators
PH12012501381A1 (en) 2010-01-15 2012-10-22 Janssen Pharmaceuticals Inc Novel substituted bicyclic triazole derivatives as gamma secretase modulators
ES2536442T3 (es) 2011-03-24 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados novedosos de triazolil piperazina y triazolil piperidina como moduladores de la gamma secretasa
CN103874702B (zh) 2011-07-15 2015-12-09 杨森制药公司 作为γ分泌酶调节剂的经取代的吲哚衍生物
CN104583208B (zh) 2012-05-16 2016-09-28 杨森制药公司 可用于治疗(尤其是)阿尔茨海默病的取代的3,4-二氢-2H-吡啶并[1,2-a]吡嗪-1,6-二酮衍生物
WO2014096212A1 (en) 2012-12-20 2014-06-26 Janssen Pharmaceutica Nv NOVEL TRICYCLIC 3,4-DIHYDRO-2H-PYRIDO[1,2-α]PYRAZINE-1,6-DIONE DERIVATIVES AS GAMMA SECRETASE MODULATORS
KR102171710B1 (ko) 2013-01-17 2020-10-30 얀센 파마슈티카 엔.브이. 감마 세크레타제 조절 인자로서의 신규 치환 피리도-피페라지논 유도체
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
KR20160134865A (ko) * 2014-04-14 2016-11-23 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 아미드 유도체 및 이의 약제학적으로 허용되는 염, 이의 제조방법 및 이의 의학적 적용
SG11201701578YA (en) * 2014-08-29 2017-03-30 Chdi Foundation Inc Probes for imaging huntingtin protein
TW202140422A (zh) 2014-10-06 2021-11-01 美商維泰克斯製藥公司 囊腫纖維化症跨膜傳導調節蛋白之調節劑
ES2946970T3 (es) 2016-03-31 2023-07-28 Vertex Pharma Regulador de conductancia transmembrana de moduladores de fibrosis quística
GEP20217329B (en) 2016-09-30 2021-12-10 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
EA202192783A1 (ru) 2016-12-09 2022-02-24 Вертекс Фармасьютикалз Инкорпорейтед Модулятор регулятора трансмембранной проводимости при муковисцидозе, фармацевтические композиции, способы лечения и способ получения указанного модулятора
EP3573615B1 (en) * 2017-01-28 2024-06-12 Kingchem Life Science LLC A process for preparing 5-phenoxy-1(3h)isobenzofuranone
MA54105A (fr) 2017-06-08 2021-09-15 Vertex Pharma Méthodes de traitement de la fibrose kystique
IL272032B2 (en) 2017-07-17 2026-04-01 Vertex Pharma Combination therapy for the treatment of cystic fibrosis including N-(1,3-DIMETHYLPYRAZOL-4-YL)SULFONYL-6-[3-(3,3,3-TRIFLUORO-2,2- DIMETHYL-PROPOXY)PYRAZOL-1-YL]-2-[(4S)-2,2,4- TRIMETHYLPYRROLIDIN-1-YL]PYRIDINE-3-CARBOXAMIDE and
MA49752A (fr) 2017-08-02 2021-04-21 Vertex Pharma Procédés de préparation de composés de pyrrolidine
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
CA3078893A1 (en) 2017-10-19 2019-04-25 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of cftr modulators
KR102716244B1 (ko) 2017-12-08 2024-10-14 버텍스 파마슈티칼스 인코포레이티드 낭포성 섬유증 막횡단 전도 조절자의 조정제의 제조 방법
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
WO2019200246A1 (en) 2018-04-13 2019-10-17 Alexander Russell Abela Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TW202317546A (zh) 2021-07-09 2023-05-01 美商普萊克斯姆公司 調節ikzf2之芳基化合物及醫藥組合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
SI1192131T1 (en) 2004-12-31
AU5312000A (en) 2001-01-02
MA26807A1 (fr) 2004-12-20
HK1046283B (zh) 2005-01-07
HK1046283A1 (en) 2003-01-03
DK1192131T3 (da) 2004-12-13
ES2223531T3 (es) 2005-03-01
BR0011446A (pt) 2002-03-19
EE200100666A (et) 2003-02-17
DE60012742D1 (de) 2004-09-09
IL146455A0 (en) 2002-07-25
AP1398A (en) 2005-04-21
DE60012742T2 (de) 2005-01-13
NO20015992L (no) 2002-02-06
EP1192131A1 (en) 2002-04-03
AU777747B2 (en) 2004-10-28
HRP20020027A2 (en) 2005-02-28
WO2000076969A1 (en) 2000-12-21
EA004405B1 (ru) 2004-04-29
EA200101133A1 (ru) 2002-06-27
GEP20043407B (en) 2004-05-10
CR6530A (es) 2004-03-24
DZ3262A1 (fr) 2000-12-12
CN1156445C (zh) 2004-07-07
ZA200109164B (en) 2003-02-06
PL352294A1 (en) 2003-08-11
ATE272623T1 (de) 2004-08-15
HUP0201586A2 (en) 2002-08-28
SK17622001A3 (sk) 2003-06-03
YU86801A (sh) 2004-07-15
NO20015992D0 (no) 2001-12-07
JP2003502313A (ja) 2003-01-21
AP2002002389A0 (en) 2002-03-31
BG106291A (bg) 2002-05-31
EP1192131B1 (en) 2004-08-04
PT1192131E (pt) 2004-11-30
CZ20014366A3 (cs) 2002-11-13
CA2373394A1 (en) 2000-12-21
KR20020012266A (ko) 2002-02-15
CN1355790A (zh) 2002-06-26
OA11958A (en) 2006-04-13
MXPA01011112A (es) 2002-06-04
TR200200257T2 (tr) 2002-06-21
NZ515619A (en) 2003-05-30
UA64842C2 (uk) 2004-03-15

Similar Documents

Publication Publication Date Title
DK1130989T3 (da) Fremgangsmåde og indretning til udtrækning af indholdet af en kapsel
DK1271537T3 (da) Fremgangsmåde og indretning til simplificering af adgangen til metadata
DK1177694T3 (da) Fremgangsmåde og system til levering af gps-
NO20015179L (no) Anordning og fremgangsmåte for venturispyling
DK1212732T3 (da) Fremgangsmåder og apparat til gennemförelse af elektroniske transaktioner
DK1226434T3 (da) Systemer og fremgangsmåder til udförelse af magnetiske kromatografianalyser
AU2001291073A1 (en) Methods and apparatus for clock management based on environmental conditions
DE60015860D1 (de) Taktrückgewinnungsschaltung und Verfahren zur Phasendetektion
DE60034814D1 (de) Bildwiederauffindungsystem und -verfahren
DK1698100T3 (da) System og fremgangsmåde til dannelse af et digitalt certifikat
NO20002908D0 (no) Anordning og fremgangsmÕte for borehullsundersøkelser
NO20021720L (no) Fremgangsmåte og system for simulering av en hydrokarbonholdig formasjon
NO20000900D0 (no) System og metode for ekstrahering av olje
DE60220300D1 (de) Schaltung zur detektion eines taktsignalverlusts und verfahren dazu
DK1192131T3 (da) Fremgangsmåde til inhibering af amyloid protein aggregering og afbildning af amyloidaflejringer under anvendelse af isoindolinderivater
IS6193A (is) Aðferð til að tálma þyrpingu amyloið protína og til að fá mynd af útfellingum þeirra
DK1219175T3 (da) Fremgangsmåde til detektion og fjernelse af ikke-aftagne skalrester på skalfisk og et apparat til udövelse af fremgangsmåden
NO20000188D0 (no) Fremgangsmåte og anordning for sidebroenntilknytning
DE60035731D1 (de) Vorrichtung zur Taktrückgewinnung
NO20012289L (no) Anordning og fremgangsmåte for innretting
DE60027629D1 (de) Magnetaufzeichnungsgerät und -methode
DE60031742D1 (de) Schaltung und Verfahren zur Steuerung eines Taktsignals und synchrone Verzögerungsschaltung
DK1345944T3 (da) Fremgangsmåde til isolering og oprensning af epothiloner
NO20011195L (no) System og fremgangsmate for raffinormalinger
NO20035392D0 (no) Digital peilemodul og fremgangsmåte for detektering